Our Solutions

September 2018

DID YOU KNOW? Algorithme Pharma, Algorithme Pharma USA and Vince & Associates Clinical Research have been part of Altasciences for over 5 years now!
Altasciences Clinical Research - Newsletter
Access Full Newsletter
MEET DR GRAHAM WOOD, Chief R&D Officer, Altasciences, Canada Top Trends Influencing the CRO Industry

Scientific Journal

A recent case study on the abuse potential of Mirogabalin, a novel α2δ ligand, and our tips on how to conduct a successful Human Abuse Potential (HAP) study.

Bioanalytical Corner

View our latest assay list and register for our upcoming bioanalytical webinars.

Industry News

Get on-demand viewing and access to the Q&A session of our webinar on examining changes in cognition in clinical pharmacology studies.

Published Articles

View our recently published articles in Pharma Tech Outlook and Clinical Trials Insight magazines to see what differentiates Altasciences from other CROs and the techniques we use to enhance safety in clinical trials.

Upcoming Acquisition

Altasciences to acquire a USA-based preclinical contract research organization, adding comprehensive safety testing services to its current full-service clinical and bioanalytical offerings. Check out all our latest news releases!

Upcoming Events

See the full lineup of events we will be attending and don’t miss our scientific presentations at the upcoming AAPS PharmSci 360 meeting on November 4-7 in Washington, DC.

» ACCESS FULL NEWSLETTER

 
Forward the newsletter Contact us Subscribe
LinkedIn Twitter Youtube
Algorithme Pharma Clinical Research Vince and Associates Clinical Research Algorithme Pharma USA Clinical Research
© 2018 Altasciences. All Rights Reserved.

THERAPEUTIC AREAS

Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide support research services and bioanalytical expertise.

Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.

Learn More